Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Merck to Market Xian Janssen's SGLT-2 Diabetes Drug in China

publication date: Jul 12, 2018

Germany's Merck KGaA will market Xian Janssen's Inovokana® in China. Inovokana, a novel treatment for type 2 diabetes, is a member of the relatively new sodium-glucose co-transporter 2 (SGLT-2) class of oral diabetes treatments. In China, Merck already distributes Glucophage® (metformin hydrochloride) and other diabetes products, while Janssen has no presence in the sector. Approved almost one year ago for China use, Inovokana is the market leader globally among SGLT-2 offerings, though it will be third to market in China. More details....

Stock Symbols: (F: MRK)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020